作者@article {hup4.2 - 049 ={你们胡锦涛和Lakshman Arcot Jayagopal和迈克尔Persenaire和安妮特Wundes和格洛丽亚·冯·Geldern}, title = {Ocrelizumab对免疫的影响参数在一群女士的病人(p4.2 - 049)},体积={92}={15}补充数量,elocation-id = {p4.2 - 049} ={2019},出版商= {Wolters Kluwer健康,公司代表美国神经病学学会},文摘={目的:检查Ocrelizumab对血清淋巴细胞亚群和免疫球蛋白的影响在实际settingBackground: Ocrelizumab是最近批准了单克隆抗体针对细胞治疗复发和主要进展型多发性硬化症(MS)。首页设计/方法:回顾性的图表总结和纵向分析的实验室和临床资料包括血清ocrelizumab患者淋巴细胞亚群和免疫球蛋白在女士在我们中心。结果:分析113例包括:55岁男性,58岁女性,平均年龄45.1岁;与复发汇款和26.6 \ 73.4 \ % %与进步女士之前大多数病人在疾病修饰治疗(85.8 \ %),而14.2 \ % treatment-na{\ \我}ve。ocrelizumab第一剂量后,所有患者有显著减少意味着酒精度和CD3(分别为24.4和11.8 \ \ % % p \ < 0.0001)和增加意味着CD4 / CD8比率13.5 \ % (p < 0.0001)。Treatment-na{\“\我}ve病人表现出显著的减少意味着酒精度,CD3, CD4, CD8和计数(40.1 \ % p = 0.02, 26.4 \ % p = 0.03, 15.8 \ % p = 0.02, 51.8 \ % p = 0.03)。病人从natalizumab证明显著减少意味着酒精度和CD4 (48.6 \ % p \ < 0.0001、25.2 \ % p = 0.006)。那些fingolimod的切换显示显著增加意味着CD3, CD4, CD8, CD4/8比率(51.1 \ % p = 0.002, 48.9 \ % p = 0.001, 25.6 \ % p = 0.012, 45.5 \ % p = 0.0001)。基线免疫球蛋白和IgM水平异常低8.1 \ %和15.6 \ %的队列。随访12个月,低免疫球蛋白水平被发现在19.8 \ %和低IgM 28.9 \ %的患者。总共有38感染但没有机会性感染被报道。没有观察到感染和搞笑状态之间的关系。结论:b细胞耗竭超出了预期,影响t淋巴球子集和免疫球蛋白水平与ocrelizumab MS患者中观察到。 While the clinical significance is undetermined, data may suggest the importance of clinical vigilance in those treated with ocrelizumab.Disclosure: Dr. Hu has nothing to disclose. Dr. Jayagopal has nothing to disclose. Dr. Persenaire has nothing to disclose. Dr. Wundes has received research support from Biogen and Alkermes. Dr. Von Geldern has nothing to disclose.}, issn = {0028-3878}, URL = {//www.ez-admanager.com/content/92/15_Supplement/P4.2-049}, eprint = {//www.ez-admanager.com/content}, journal = {Neurology} }